Isolated peptides derived from SEQ ID NO: 50 and fragments thereof that bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL) and thus are suitable for use in the context of cancer immunotherapy, more particularly cancer vaccines are described herein. The inventive peptides encompasses both the above mentioned amino acid sequences and modified versions thereof, in which one, two, or several amino acids sequences substituted, deleted, added or inserted, provided such modified versions retain the requisite cytotoxic T cell inducibility of the original sequence. Further provided are nucleic acids encoding any of the aforementioned peptides as well as pharmaceutical agents, substances and/or compositions that include or incorporate any of the aforementioned peptides or nucleic acids. The peptides, nucleic acids, pharmaceutical agents, substances and compositions of this invention find particular utility in the treatment of cancers and tumors, including, for example, AML, bladder cancer, breast cancer, cervical cancer, cholangiocellular carcinoma, CML, colorectal cancer, esophagus cancer, Diffused-type gastric cancer, liver cancer, NSCLC, lymphoma, osteosarcoma, ovarian cancer, pancreatic cancer, prostate cancer, renal carcinoma, SCLC, soft tissue tumor and testicular tumor.Linvention concerne des peptides isolés dérivés de SEQ ID NO : 50 et leurs fragments qui se lient à un antigène HLA et induisent des lymphocytes T cytotoxiques (CTL), et sont par conséquent appropriés pour une utilisation dans le contexte de limmunothérapie du cancer, plus particulièrement des vaccins du cancer. Les peptides selon linvention comprennent à la fois les séquences dacides aminés susmentionnées et leurs versions modifiées dans lesquelles une, deux séquences dacides aminés ou plus sont remplacées, supprimées, ajoutées ou insérées, à condition que de telles versions modifiées conservent la capacité dinduction des cellules T cytotoxiques requise de la séquence initiale. Linvention c
